Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
The primary objective of this study is to evaluate whether the addition of ibrutinib to bendamustine and rituximab will result in prolongation of PFS in subjects with newly diagnosed MCL who are 65 years of age or older.
Critère d'inclusion
- Mantle cell lymphoma